AU2006340002B2 - Glucagon receptor antagonists, preparation and therapeutic uses - Google Patents

Glucagon receptor antagonists, preparation and therapeutic uses Download PDF

Info

Publication number
AU2006340002B2
AU2006340002B2 AU2006340002A AU2006340002A AU2006340002B2 AU 2006340002 B2 AU2006340002 B2 AU 2006340002B2 AU 2006340002 A AU2006340002 A AU 2006340002A AU 2006340002 A AU2006340002 A AU 2006340002A AU 2006340002 B2 AU2006340002 B2 AU 2006340002B2
Authority
AU
Australia
Prior art keywords
butyl
compound
alkyl
methyl
halogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006340002A
Other languages
English (en)
Other versions
AU2006340002A1 (en
Inventor
Scott Eugene Conner
Jianke Li
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2006340002A1 publication Critical patent/AU2006340002A1/en
Application granted granted Critical
Publication of AU2006340002B2 publication Critical patent/AU2006340002B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2006340002A 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses Ceased AU2006340002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73762705P 2005-11-17 2005-11-17
US60/737,627 2005-11-17
PCT/US2006/060586 WO2007106181A2 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (2)

Publication Number Publication Date
AU2006340002A1 AU2006340002A1 (en) 2007-09-20
AU2006340002B2 true AU2006340002B2 (en) 2011-12-22

Family

ID=38474434

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006340002A Ceased AU2006340002B2 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Country Status (14)

Country Link
US (1) US7696248B2 (enExample)
EP (1) EP1951661B1 (enExample)
JP (1) JP5107253B2 (enExample)
CN (1) CN101309895B (enExample)
AU (1) AU2006340002B2 (enExample)
BR (1) BRPI0618349A2 (enExample)
CA (1) CA2629348C (enExample)
CY (1) CY1113159T1 (enExample)
DK (1) DK1951661T3 (enExample)
ES (1) ES2391109T3 (enExample)
PL (1) PL1951661T3 (enExample)
PT (1) PT1951661E (enExample)
SI (1) SI1951661T1 (enExample)
WO (1) WO2007106181A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5000492B2 (ja) * 2004-06-14 2012-08-15 イーライ リリー アンド カンパニー グルカゴン受容体拮抗物質及びその調製並びに治療的使用
DK2129654T3 (da) 2007-02-09 2014-08-25 Metabasis Therapeutics Inc Antagonister af glucagonreceptoren
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5465658B2 (ja) * 2008-03-05 2014-04-09 武田薬品工業株式会社 複素環化合物
PL2799428T3 (pl) 2008-08-13 2017-05-31 Metabasis Therapeutics, Inc. Antagoniści glukagonu
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
TWI475018B (zh) * 2009-02-06 2015-03-01 Takeda Pharmaceutical 雜環化合物
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2822017C (en) * 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
GEP20156351B (en) 2011-02-08 2015-08-25 Pfizer Glucagon receptor modulator
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DK2714661T3 (en) * 2011-05-23 2015-10-19 Janssen Pharmaceutica Nv PICOLINAMIDO - propanoic APPLICABLE TO glucagon receptor antagonists
PL2714647T3 (pl) * 2011-05-23 2015-09-30 Janssen Pharmaceutica Nv Pochodne bifenylu przydatne jako antagoniści receptora glukagonu
CN103732578B (zh) * 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9073864B2 (en) 2012-03-29 2015-07-07 Takeda Pharmaceutical Company Limted Aromatic ring compound
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
JP2016052300A (ja) * 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014789A1 (en) * 2001-12-03 2004-01-22 Jesper Lau Novel glucagon antagonists/inverse agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
ATE307798T1 (de) * 1999-05-17 2005-11-15 Novo Nordisk As Glucagon antagonisten/inverse agonisten
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2004056763A2 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Novel glucagon antagonists
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014789A1 (en) * 2001-12-03 2004-01-22 Jesper Lau Novel glucagon antagonists/inverse agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KURUKULASURIYA, R. et al., Biorg. Med. Chem. Lett., 2004, Vol. 14, pages 2047-2050 *

Also Published As

Publication number Publication date
CA2629348C (en) 2013-08-13
PT1951661E (pt) 2012-09-19
CA2629348A1 (en) 2007-09-20
WO2007106181A3 (en) 2007-12-06
ES2391109T3 (es) 2012-11-21
WO2007106181A2 (en) 2007-09-20
JP2009519226A (ja) 2009-05-14
JP5107253B2 (ja) 2012-12-26
DK1951661T3 (da) 2012-09-03
SI1951661T1 (sl) 2012-11-30
US7696248B2 (en) 2010-04-13
CN101309895B (zh) 2012-10-03
BRPI0618349A2 (pt) 2011-08-23
US20080300308A1 (en) 2008-12-04
PL1951661T3 (pl) 2012-12-31
AU2006340002A1 (en) 2007-09-20
EP1951661A2 (en) 2008-08-06
EP1951661B1 (en) 2012-08-08
CY1113159T1 (el) 2016-04-13
CN101309895A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
AU2006340002B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
AU2006342449B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1957068B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629311C (en) Glucagon receptor antagonists, preparation and therapeutic uses
AU2006341392B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired